StreetInsider.com News Articles

Revelation Biosciences sets 1-for-7 reverse stock split for Oct. 20

Fri, 16 Oct 2026 09:00:30 -0400

Revelation Biosciences, Inc. (NASDAQ: REVB) announced it will implement a 1-for-7 reverse split of its common stock, effective Oct. 20, 2026, according to a press release from the San Diego-based clinical-stage life sciences company.

The stock will begin trading on a post-split basis under the existing ticker symbol "REVB" at the start of trading on that date. The new CUSIP number for the common stock will be 76135L887.

The company stated the reverse stock split is intended to increase the market price per share of its common stock to regain compliance with the minimum bid continued listing requirement of the Nasdaq Capital

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

Fri, 16 Oct 2026 09:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “REVB.” The CUSIP number for the common stock

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

Fri, 16 Oct 2026 09:00:00 -0400

Form 8-K REVELATION BIOSCIENCES, For: Aug 17

Wed, 19 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260819/26951038.html

Form 8-K REVELATION BIOSCIENCES, For: Aug 17

Wed, 19 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260819/26951038.html

Revelation Biosciences picks Avance Clinical for kidney injury trial

Wed, 19 Aug 2026 09:00:42 -0400

Revelation Biosciences, Inc. (NASDAQ: REVB) has selected Avance Clinical as the contract research organization (CRO) for its Phase 2/3 adaptive-design TITAN study evaluating its drug candidate Gemini in patients with acute kidney injury (AKI), according to a press release.

The company said the study is on track to begin later this year. Avance Clinical will be responsible for site identification and management, patient recruitment, safety monitoring, and data management for the trial.

"The Company selected Avance Clinical following an extensive evaluation process," said James Rolke, Chief Executive Officer of Revelation. "Working closely with Avance, the Revelation team remains committed to starting this

Revelation Biosciences picks Avance Clinical for kidney injury trial

Wed, 19 Aug 2026 09:00:42 -0400

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Wed, 19 Aug 2026 09:00:00 -0400

– Study on track to begin later this year –

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI).

The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Wed, 19 Aug 2026 09:00:00 -0400

– Study on track to begin later this year –

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI).

The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Wed, 19 Aug 2026 09:00:00 -0400

– Study on track to begin later this year –

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI).

The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Wed, 19 Aug 2026 09:00:00 -0400

– Study on track to begin later this year –

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI).

The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the

Form 4 REVELATION BIOSCIENCES, For: Aug 17 Filed by: CARVER JENNIFER